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Abstract: Cold preservation is the standard of care for renal grafts. However, research on alternatives
like perfusion at higher temperatures and supplementing preservation solutions with hydrogen
sulfide (H2S) has gained momentum. In this study, we investigated whether adding H2S donor AP39
to porcine blood during subnormothermic perfusion at 21 ◦C improves renal graft outcomes. Porcine
kidneys were nephrectomized after 30 min of clamping the renal pedicles and treated to 4 h of static
cold storage (SCS) on ice or ex vivo subnormothermic perfusion at 21 ◦C with autologous blood
alone (SNT) or with AP39 (SNTAP). All kidneys were reperfused ex vivo with autologous blood
at 37 ◦C for 4 h. Urine output, histopathology and RNAseq were used to evaluate the renal graft
function, injury and gene expression profiles, respectively. The SNTAP group exhibited significantly
higher urine output than other groups during preservation and reperfusion, along with significantly
lower apoptotic injury compared to the SCS group. The SNTAP group also exhibited differential
pro-survival gene expression patterns compared to the SCS (downregulation of pro-apoptotic genes)
and SNT (downregulation of hypoxia response genes) groups. Subnormothermic perfusion at 21 ◦C
with H2S-supplemented blood improves renal graft outcomes. Further research is needed to facilitate
the clinical translation of this approach.
Keywords: AP39; hydrogen sulfide; subnormothermic perfusion; kidney preservation; ischemia–
reperfusion injury; donation after cardiac death; porcine model
1. Introduction
Over the past 25 years, hydrogen sulfide (H2S) has become known as the third gaso-
transmitter, following nitric oxide and carbon monoxide, and the body of literature about
its roles in all cells and tissues continues to expand [1–3]. One interesting therapeutic appli-
cation of H2S is its use in kidney graft preservation to improve renal transplant outcomes.
Renal transplantation is the preferred treatment for end stage renal disease, because it
enhances the quality of life and survival compared to hemodialysis [4]. The demand for
transplantable kidneys, however, outweighs the supply. As a result, kidneys obtained via
donation after cardiac death (DCD) are being used more often in transplant centers across
the globe [5]. DCD kidneys typically exhibit higher rates of delayed graft function (DGF)
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and poor long-term survival [6,7]. This is due to the greater ischemic injury experienced
by DCD grafts compared to living donor organs. Kidneys from living donors experience
some cold ischemic injury from the time of harvest to reimplantation. However, DCD
kidneys experience prolonged periods of warm ischemia, as cardiac death occurs, and cold
ischemia, during organ preservation. This leads to more severe ischemia–reperfusion injury
(IRI) upon reimplantation, which contributes to DGF and other poor outcomes exhibited
by DCD kidneys [8].
Organ preservation is a critical phase in terms of mitigating IRI. The clinical standard
of care for renal graft preservation is static cold storage (SCS), where the organ is placed on
ice (~4 ◦C) in a bag with preservation solution. The alternative is hypothermic machine
perfusion (HMP), where the organ is perfused with cold preservation solution. While
this approach improves the distribution of nutrients and improves DCD graft outcomes
compared to SCS [9,10], it is used less frequently due to its higher cost and logistical
challenges [11,12]. Importantly, both approaches are limited by the shutdown of cellular
metabolism inherent to cold preservation, which causes renal injury while improving
survival in cold conditions. Longer cold ischemia times are linked to poorer DCD graft
outcomes, including higher rates of DGF [13]. As a result, therapeutic strategies that
mitigate cold IRI are of interest. One therapeutic approach is supplementing preservation
solutions with H2S due to its vasodilatory, anti-apoptotic and other cytoprotective effects
during IRI [14–16]. We have previously shown that supplementing preservation solutions
with H2S, especially mitochondria-targeted H2S donor AP39, during SCS improves murine
renal graft outcomes [15,16]. However, the context of cold preservation remains. Thus,
alternative approaches that facilitate kidney preservation at higher temperatures (20–37 ◦C)
are also of interest [17].
Normothermic machine perfusion, which involves ex vivo perfusion of the kidney
at 37 ◦C with blood-based or acellular solutions, has been shown to improve renal graft
outcomes compared to SCS and HMP in several porcine DCD renal transplantation stud-
ies [18,19]. In a 2011 pilot surgical case, it was reported that a short duration of this approach
after SCS improved the clinical post-transplant outcomes compared to SCS alone [20]. Ad-
ditionally, several ongoing clinical trials are looking to validate and establish a clinical
protocol for normothermic preservation. However, in moving away from cold preservation,
research into subnormothermic preservation at different temperatures (15–35 ◦C) has also
gained momentum. In 2014, Hoyer et al. reported that, compared to SCS and HMP, the sub-
normothermic machine perfusion of DCD porcine kidneys at 20 ◦C improved blood flow,
output and creatinine clearance during reperfusion with autologous blood [21]. Our group
has previously shown that adding AP39 to the University of Wisconsin (UW) solution, a
preservation solution that is routinely used for SCS, made it viable for subnormothermic
preservation at 21 ◦C [22]. We also showed that subnormothermic perfusion at 21 ◦C im-
proved DCD porcine renal graft outcomes compared to SCS, subnormothermic perfusion
at 15 ◦C and normothermic perfusion at 37 ◦C [23]. In this study, we investigate whether
subnormothermic perfusion at 21 ◦C with H2S donor AP39 improves DCD porcine renal
graft outcomes compared to SCS and subnormothermic perfusion without AP39, using ex
vivo pulsatile perfusion for preservation and reperfusion.
2. Materials and Methods
2.1. Animal Care and Surgery
Ten Yorkshire pigs (60–70 kg), purchased from a regional farm, were tranquilized and
routinely prepped for surgery. A midline incision was used to expose the kidneys (n = 20).
The renal pedicles were clamped in situ for 30 min to induce warm ischemia, to mimic
DCD injury, following an intravenous infusion of 10,000 units of heparin. By completely
stopping the renal blood flow, we replicated an extreme clinical DCD scenario where there
was no oxygen being supplied to the kidneys. This approach has been used in many other
studies within this field [18,21]. The ureters and arteries were cannulated to facilitate ex
vivo perfusion and urine collection. Subsequently, both kidneys were nephrectomized,
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and the donor animal was euthanized. Autologous blood used for perfusion was collected
via cannulation of the inferior vena cava before and after clamping the renal pedicles [23].
Blood collected prior to clamping is referred to as non-stressed blood, because there is
no interruption of the blood flow. However, blood collected after clamping is referred
to as stressed blood due to the buildup of metabolites and signaling molecules resulting
from the lack of blood flow through the kidneys. Surgeries were performed by transplant
fellows at University Hospital, London, ON, Canada. All procedures were approved by
the University of Western Ontario’s Animal Use Committee.
2.2. Treatments and Ex Vivo Perfusion Setup
The kidneys were assigned to one of three preservation treatments (Figure 1A). The
first group of kidneys was flushed with and stored in UW solution on ice for 4 h (SCS),
which reflects the clinical standard of care. The second group of kidneys was flushed with
UW solution and treated to 4 h of subnormothermic perfusion at 21 ◦C with non-stressed
blood (SNT). The third group of kidneys was flushed with UW solution supplemented with
200 nM AP39 and treated to 4 h of subnormothermic perfusion at 21 ◦C with non-stressed
blood supplemented with 200 nM AP39 (SNTAP). After the 4 h preservation period,
all kidneys were perfused with stressed autologous blood for 4 h at 37 ◦C to simulate
reperfusion after renal transplantation. A total of ten pig kidney perfusion experiments
were performed. In the first seven experiments, left and right kidneys were randomly
assigned to either the SCS group (n = 7) or the SNTAP group (n = 7), with both kidneys
connected to the same cassette during reperfusion with stressed blood. Pairs of kidneys
sharing the blood reservoir was unavoidable due to the limitation of having a single
pulsatile pump. In the following three experiments, both the left and right kidneys were
assigned to the SNT group (n = 6), as this was an additional control group to represent the
effects of subnormothermic perfusion without AP39. The dose of AP39 was chosen based
on a previous in vivo murine transplantation study by our group [10]. The kidneys were
perfused using an ex vivo pulsatile perfusion apparatus (Figure 1B), which was identical to
the setup used in a previous study by our center [23]. Through adjusting the flow, the mean
perfusion pressure was maintained at 60 mmHg after an initial 5-min period of gradual
increase. The blood used in the perfusion circuits was oxygenated using an external oxygen
gas supply, and no supplemental nutrients, vasodilators or diuretics were added at any
point. This was done to evaluate the effect of subnormothermic perfusion with and without
AP39 compared to SCS in a simplistic manner, without any confounding variables. The
urine output was recorded hourly, and PlasmaLyte solution (Baxter, Deerfield, IL, USA)
was used to compensate for the fluid volume loss. Kidney samples were collected after
reperfusion with stressed blood, and kidneys were bivalved sagittally. One half was stored
at −80 ◦C for the RNA sequencing (RNAseq) analysis, and the other half was stored in
formalin for histopathological analyses.
2.3. AP39
AP39, synthesized in-house by Prof. Whiteman [24] (Exeter, UK), was dissolved in
dimethyl sulfoxide to achieve a 1 mM stock concentration. Two hundred microliters of the
stock was added to 1 L bags of preservation solution used for flushing, and blood used for
perfusion, to achieve a treatment concentration of 200 nM AP39 [15].
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Figure 1. Summary of the methods. (A) Overview of the experimental design. (B) Schematic of the ex vivo perfusion setup
used for porcine kidney perfusion and reperfusion. (C) RNAseq analysis workflow.
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2.4. Histopathology Imaging and Quantification
The formalin-fixed kidney sections, including cortex and medulla, were stained with
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), along with Hema-
toxylin and Eosin (H&E), to determine the level of apoptosis and acute tubular necrosis
(ATN), respectively. TUNEL and H&E imaging was done using the Nikon Instruments
Eclipse 90i digital microscope at 10× magnification (Nikon Instruments, Melville, NY,
USA). To quantify the apoptotic injury, 10 random images of TUNEL staining were cap-
tured per sample. The images were run through ImageJ v.1.50 (National Institute of Health,
Bethesda, MD, USA) to determine the %TUNEL+ area, the ratio of the brown tubular area
(TUNEL+) and the total tubular area. To quantify the ATN, H&E slides were scored for
ATN by a blinded renal pathologist, as per the following scheme: 1 = <11%, 2 = 11–24%,
3 = 25–45%, 4 = 46–75% and 5 = >75%.
2.5. Statistical Analysis
GraphPad Prism 8 was used to create graphs and conduct statistical analyses. Stu-
dent’s t-test or one-way ANOVA followed by Tukey’s post-hoc test were used for com-
parisons of two or three experimental groups, respectively. Statistical significance was
accepted at p < 0.05.
2.6. RNASeq
Total RNA was extracted from frozen renal cortical tissues using RNEasy kits (Qiagen,
Toronto, ON, Canada) following the vendor’s protocols. Total RNA samples were quanti-
fied using NanoDrop (Thermo Fisher Scientific, Waltham, MA, USA), and the quality was
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Mississauga, ON,
USA) and the RNA 6000 Nano kit (Caliper Life Sciences, Hanover, MD, USA). They were
then processed using the Vazyme VAHTS Total RNA-seq (H/M/R) Library Prep Kit for
Illumina (Vazyme, Nanjing, Jiangsu, China), which includes rRNA reduction. Three sam-
ples (n = 3) from each experimental group and one control sample from a baseline porcine
kidney with no DCD injury (CTR, n = 1) were sequenced at the London Regional Genomics
Centre (Robarts Research Institute, London, ON, Canada) using Illumina NextSeq 500
(Illumina Inc., San Diego, CA, USA).
Briefly, samples were rRNA-depleted, then fragmented. cDNA was synthesized,
indexed, cleaned up and amplified via PCR. Libraries were then equimolarly pooled into
one library, and the size distribution was assessed on an Agilent High-Sensitivity DNA
Bioanalyzer chip and quantified using the Qubit 2.0 Fluorimeter (Thermo Fisher Scientific,
Waltham, MA, USA). The library was sequenced on an Illumina NextSeq 500 as a single end
run, 1 × 76 bp, using a High Output v2 kit (75 cycles). Fastq data files were downloaded
from BaseSpace and analyzed using Partek Flow (Partek, Chesterfield, MO, USA). After
importation, data was aligned to the Sus scrofa genome using STAR 2.6.1d and annotated
using Ensembl v 97.
The resulting raw gene counts were analyzed using a workflow summarized in
Figure 1C. A final gene counts file was prepared after removing the genes that could
not be annotated using Ensembl Biomart and genes that did not have matching human
gene IDs approved by the HUGO Gene Nomenclature Committee, which is necessary for
functional enrichment analysis. Using RStudio v. 3.6.1 (Boston, MA, USA; session info
in Appendix A), sample distribution mapping and principal component analysis were
performed to visualize the difference in the expression profiles of the samples in each
group. The DESeq2 package was used to identify the differentially expressed genes for the
following comparisons: SNTAP vs. SCS and SNTAP vs. SNT (alpha = 0.05). Based on the
protocol detailed by Reimand et al. [25], Gene Ontology (GO) annotations were found for
the differentially expressed genes using g:Profiler. These annotations were analyzed using
Cytoscape v.3.7.2 to develop network enrichment maps, which facilitated the identification
of certain genes and pathways of interest for both comparisons.
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3. Results
3.1. Subnormothermic Perfusion with AP39-Supplemented Blood Improves Urine Output and
Reduces Tissue Injury Compared to Static Cold Storage and Subnormothermic Perfusion
without AP39
To investigate whether subnormothermic perfusion with AP39-supplemented blood
can improve ex vivo DCD renal graft function, porcine kidneys were assigned to four h
of cold storage or subnormothermic perfusion with non-stressed blood at 21 ◦C, with or
without AP39. During preservation, DCD kidneys perfused with AP39-supplemented
blood (SNTAP group) exhibited significantly higher (p < 0.05) urine output than the
kidneys perfused with blood on their own (SNT group) (Figure 2A). No urine output was
recorded for the static cold storage (SCS group), as those kidneys were placed on ice. The
preservation period was followed by four h of reperfusion with stressed blood at 37 ◦C.
During reperfusion, the SNTAP group also exhibited significantly higher urine output than
the SCS group (p < 0.05) and the SNT group (p < 0.01). No significant difference in urine
output was observed between the SCS and SNT groups (Figure 2B). Following reperfusion,
the kidneys were sagittally bivalved, and formalin-fixed sections were stained with TUNEL
and H&E to determine apoptotic injury and ATN, respectively (Figure 3A). The SNTAP
group exhibited the lowest mean %TUNEL+ area and mean ATN score (Figure 3B,C).
While no statistically significant differences were found amongst the mean ATN scores
(Figure 3C), the SNTAP group exhibited significantly lower mean %TUNEL+ area than the
SCS group (p < 0.05), indicating significantly lower apoptotic injury (Figure 3B).
Figure 2. Subnormothermic perfusion with AP39 improves urine output during preservation and reperfusion. Porcine
kidneys were nephrectomized after 30 min of clamping to mimic donation after cardiac death (DCD) injury and subjected
to various preservation treatments for 4 h. This was followed by 4 h of reperfusion with stressed autologous blood. Urine
output was collected during both perfusion periods for all groups, except for the static cold storage group, where kidneys
were on ice during the 4 h of preservation. (A) Total urine output (mL) collected during 4 h of preservation perfusion. (B)
Total urine output (mL) collected during 4 h of reperfusion with stressed blood. Lines represent mean ± SEM. Values in (A)
were compared using a student’s unpaired t-test, and values in (B) were compared using one-way ANOVA followed by
Tukey’s post-hoc test. * p < 0.05 and ** p < 0.01. Circles represent values for static cold storage (SCS, n = 7). Squares represent
values for subnormothermic perfusion (SNT, n = 6). Triangles represent values for subnormothermic perfusion with 200 nM
AP39 (SNTAP, n = 7).
Biomolecules 2021, 11, 446 7 of 16
Figure 3. Subnormothermic perfusion with AP39 reduces tissue apoptosis and acute tubular necrosis.
(A) Representative Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) and
Hematoxylin and Eosin (H&E) images of formalin-fixed DCD kidney sections after 4 h of preservation
treatment and 4 h of reperfusion. Images were taken at 10× magnification (scale bar = 100 µm).
(B) Mean %TUNEL+ area, as determined by ImageJ, using a ratio of the TUNEL+ area (brown) to
total tubular area. Each individual data point represents the mean %TUNEL+ area of 10 random
fields of view of one porcine kidney sample. (C) Acute tubular necrosis (ATN) scores based on H&E
staining. Each individual data point represents the score assigned to one porcine kidney sample.
Lines in (B,C) represent the means ± SEM. Values in (B,C) were compared using one-way ANOVA
followed by Tukey’s post-hoc test. * p < 0.05. Circles represent values for static cold storage (SCS,
n = 7). Squares represent values for subnormothermic perfusion (SNT, n = 6). Triangles represent
values for subnormothermic perfusion with 200 nM AP39 (SNTAP, n = 7).
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3.2. Adding AP39 to Blood During Subnormothermic Perfusion Leads to Differential Pro–Survival
Gene Expression Patterns Compared to Static Cold Storage and Subnormothermic Perfusion
without AP39
To investigate the effect of AP39 on gene expression in this study, RNAseq was per-
formed on frozen porcine kidney sections collected after reperfusion. Using RStudio, a
principal component analysis was performed to visualize the kidney samples in all groups
(Figure 4). Using the DESeq2 package in RStudio, it was determined that 214 genes were
differentially expressed in the SNTAP group vs. the SCS group (alpha = 0.05, Figure S1 in
the Supplementary Materials, which is available online). Through the network enrichment
analysis, clusters of interest were identified based on GO annotations for the 214 genes,
including the response to heat, response to stress, regulation of transcription and negative
regulation of cell death (Figure 5A). Relative to the SCS group, the SNTAP group exhibited
downregulation of pro-apoptotic (BCL10) and heat shock response (HSPD1 and HSPA1A)
genes, along with regulators of those pathways (BAG3 and DDIT3). Additionally, pro-
liferation (MAPK7) and oxidative stress response (NRROS) genes were upregulated in
the SNTAP group (Figure 5B). Next, it was determined that 614 genes were differentially
expressed in the SNTAP group vs. the SNT group (alpha = 0.05). Clusters of interest
were identified based on GO annotations, including the response to hypoxia, regulation of
transcription and response to endogenous stimulus (Figure 6A). Relative to the SNT group,
several genes associated with the HIF-1α-mediated hypoxia response pathway (EGR1,
PCK1, PDK3 and RGCC) were downregulated in the SNTAP group. The expression of
genes mediating the transforming growth factor beta (TGF-β) pathway (SMAD3 and NR-
ROS) and HIF-1α degradation (AJUBA) was upregulated in the SNTAP group (Figure 6B).
Additionally, the downregulation of proinflammatory (IL6 and HMGB2) and pro-cell death
(HOXD8, HOXD10) genes was observed in the SNTAP group, along with upregulation of
proliferation (MAPK7) and oxidative stress response (NRROS) genes (Figure 6C).
Figure 4. Principal component analysis of r-log normalized gene counts for all porcine kidney
samples. Frozen renal cortical sections were used for the RNAseq analysis. RStudio was used to
perform the principal component analysis with the full set of r-log normalized gene counts for all
samples and to visualize the clustering of samples by group. CTR, control baseline kidney with no
DCD injury or preservation treatment (n = 1). SCS, static cold storage (n = 3). SNT, subnormothermic
perfusion (n = 3). SNTAP, subnormothermic perfusion with 200 nM AP39 (n = 3). Numbers following
group names denote individual samples.
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Figure 5. Gene expression analysis after preservation using subnormothermic perfusion with AP39 vs. static cold storage.
Frozen renal cortical sections (n = 3 for each group) were used for the RNAseq analysis. Differentially expressed genes
were identified using RStudio (DESeq2; alpha = 0.05). Gene Ontology (GO) annotations were found for those genes
using g:Profiler, and the network enrichment analysis was performed using Cytoscape. (A) Network enrichment map
showing certain nodes of interest (FDR Q value < 1.0 and Jaccard Overlap combined coefficient > 0.375 with a combined
constant = 0.5). (B) Gene expression values (log2 fold change ± SEM, determined using RStudio) of certain genes of interest
chosen from three nodes of interest from the enrichment map in (A)—response to stress, negative regulation of the apoptotic
process and regulation of the DNA-templated transcription in response to stress.
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Figure 6. Gene expression analysis after preservation using subnormothermic perfusion with or
without AP39. Frozen renal cortical sections (n = 3 for each group) were used for the RNAseq analysis.
Differentially expressed genes were identified using RStudio (DESeq2, alpha = 0.05). GO annotations
were found for those genes using g:Profiler, and the network enrichment analysis was performed
using Cytoscape. (A) Network enrichment map showing certain nodes of interest (FDR Q value
< 1.0 and Jaccard Overlap combined coefficient > 0.375 with a combined constant = 0.5). (B) Gene
expression values (log2 fold change ± SEM, determined using RStudio) of all the genes in the three
connected nodes from the enrichment map in (A)—response to oxygen levels, hypoxia and decreased
oxygen levels. (C) Gene expression values (log2 fold change ± SEM, determined using RStudio) of
certain genes of interest from two nodes of interest from the enrichment map in (A)—regulation of
the DNA-templated transcription and response to the endogenous stimulus.
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4. Discussion
This study shows that subnormothermic perfusion of DCD pig kidneys with AP39-
supplemented blood (SNTAP) improves the urine output, reduces tissue injury and leads
to differential pro-survival gene expression compared to static cold storage (SCS) and
subnormothermic perfusion with blood alone (SNT) in our ex vivo model of preservation
(four hours) and reperfusion (four hours).
The SNTAP group displayed a significantly higher urine output than the SNT group
during preservation and both the SNT and SCS groups during reperfusion. This is likely
due to an increase in vasodilation leading to greater renal blood flow (RBF) and subsequent
diuresis. Vasoconstriction is a critical consequence of warm ischemic injury during DCD
organ procurement and cold ischemic injury during SCS or HMP [26]. H2S has been shown
to enhance vasodilation and RBF in several studies. Xia et al. showed that the infusion of
NaHS in the intrarenal arteries of rats enhanced RBF and the glomerular filtration rate [27].
Additionally, using a porcine model of renal transplantation, Hosgood and Nicholson
showed that the infusion of H2S ten minutes prior to and after reperfusion improves
RBF and renal function [28]. Previous studies have also shown that H2S inhibits platelet
aggregation in vitro and in vivo [29,30], which could contribute to increased blood flow.
Although AP39 has not been directly linked to RBF or platelet aggregation to date, our
RNAseq results (discussed below) suggest a potential vasodilatory mechanism that may
contribute to the significantly higher urine output of the SNTAP group.
The SNTAP group also exhibited significantly lower tissue apoptosis than the SCS
group, based on TUNEL staining. This finding was supported by the downregulation of
pro-apoptotic genes in the SNTAP group relative to the SCS group. Several studies have
reported that AP39 reduces renal apoptosis [15,31,32], and it has been shown to downregu-
late Bax [32], a pro-apoptotic gene in the intrinsic apoptotic pathway. This study shows, for
the first time, that AP39 may be exerting anti-apoptotic effects through downregulating
BCL10 [33,34], a pro-apoptotic regulatory gene, and DDIT3 [35], a transcriptional regulator
of endoplasmic reticulum stress-induced apoptosis. Notably, the expression of heat shock
proteins (HSPD1 and HSPA1A) and BAG3, an HSP cochaperone [36], was downregulated
in the SNTAP group. Seeing as these factors normally promote cell survival during heat-
induced stress [37,38], it is counterintuitive that they are downregulated in the SNTAP
group (21 ◦C) compared to the SCS group (4 ◦C). However, the resulting anti-survival
effects are likely counteracted by the downregulation of apoptotic genes and upregulation
of MAPK7, a key mediator of cell proliferation and cell survival [39].
Interestingly, several genes associated with the HIF1α-mediated hypoxia response,
which contributes to acute kidney injury and renal IRI [40], were downregulated in the
SNTAP group relative to the SNT group. The downregulation of PCK1 [41] and PDK3,
metabolic targets activated by HIF1α [42], may help with managing the metabolic demand
at 21 ◦C that is not being met with metabolites, thereby mitigating tissue injury. The
downregulation of RGCC, a negative regulator of HIF1α-mediated angiogenesis [43], and
EGR1, a negative coregulator of erythropoietin-receptor expression [44], likely promotes
vascularization. This may contribute to the improved urine output of the SNTAP group
through improving the RBF. The upregulation of AJUBA, a mediator of HIF1α degra-
dation [45], likely helps to balance the positive and negative effects of HIF1α and other
genes associated with it. Additionally, the SNTAP group exhibited downregulation of the
pro-apoptotic genes (HOXD8 and HOXD10) [46,47], which could further explain the lower
tissue apoptosis in the SNTAP group.
The SNTAP group also exhibited upregulation of MAPK7 and NRROS compared to
both the SCS and SNT groups. AP39 has been shown to reduce reactive oxygen species
(ROS) levels in vitro [15,32]. The downregulation of NRROS, which negatively regulates
ROS production [48] and activates TGF-β1 [49,50], could underlie the antioxidant and pro-
tective responses observed by previous studies on AP39. Additionally, the downregulation
of IL6 was observed in the SNTAP group relative to the SNT group, which matches the
findings of a previous study looking at the effect of AP39 in myocardial IRI [32]. IL6 is
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a key proinflammatory cytokine in the progression of acute kidney injury [51], and its
downregulation by AP39 may contribute to the improved outcomes of the SNTAP group
compared to the SNT group.
There are two limitations to the perfusion model used in this study. Firstly, the per-
fusion times used are relatively short. However, the four-hour duration was deemed
appropriate, because this was the first time that our novel approach towards organ preser-
vation was attempted on large mammalian kidneys, and hence, we wanted to prove its
feasibility. Further testing using longer periods of preservation and reperfusion will be nec-
essary for clinical translation. Secondly, the limitation of having only one organ perfusion
pump due to financial constraints required us to place the two kidneys on the same circuit
during the reperfusion phase; however, the urine output from each kidney was collected
separately. Perfusing both kidneys on separate pumps would have prevented their metabo-
lites from pooling into a shared blood reservoir. Despite this limitation, the SNTAP group
exhibited significantly higher urine output during reperfusion and a significantly lower
TUNEL score than the SCS group. This suggests that if we had reperfused the kidneys
on two separate pumps, our positive findings would have been accentuated to a greater
extent, which further supports the use of our novel approach.
While the number of samples we could perform RNAseq testing on was limited by
the cost, the consistency in gene expression across the samples in most groups facilitated a
reliable analysis within the constraints of this limitation. Additionally, the findings of our
study were strengthened by the approach of clamping the renal pedicle to mimic a DCD
injury. Inducing the complete cessation of the RBF via clamping mimics an extreme clinical
DCD scenario where no oxygen is supplied to the kidneys. Thus, the positive outcomes
observed in this study are more likely to translate to and be accentuated in real clinical
DCD scenarios where there is a more gradual cessation of blood flow as cardiac death
occurs. Evidently, further in vitro research is needed to confirm the mechanisms underlying
AP39′s protective effects. Future studies using in vivo models of renal transplantation and
clinically approved H2S donors are also needed to support the findings of this study.
In conclusion, this study demonstrates that subnormothermic perfusion with AP39-
supplemented blood can improve ex vivo DCD porcine renal graft function. We postulate
that the subnormothermic temperature allows for maintenance of the vasculature, unlike
static cold storage, with a metabolic demand that is lower than normal due to the deviation
from the physiological temperature (37 ◦C). The presence of H2S helps mitigate some of
the negative consequences of being unable to meet the metabolic demand at 21 ◦C in a
nutrient-deficient environment, such as inflammation, ROS and apoptosis. Overall, this
study adds to the growing body of literature that supports the use of subnormothermic
temperatures and H2S in organ preservation to improve DCD renal graft outcomes. These
strategies could facilitate the use of more marginal grafts, which could increase the pool of
transplantable organs.
5. Patent
The data reported in this study is a part of a US patent application (serial no. 17/127,965
entitled “Method and Compositions for Protecting Tissue”) that is pending approval. Addi-
tionally, Prof. Matthew Whiteman and the University of Exeter have intellectual property
(patent filings) related to hydrogen sulfide delivery molecules and their therapeutic use.
Supplementary Materials: The following are available online at https://www.mdpi.com/2218-273
X/11/3/446/s1: Figure S1: Heatmap of the differential gene expression analysis after preservation
using subnormothermic perfusion with AP39 vs. static cold storage. Porcine kidneys were nephrec-
tomized after 30 min of clamping to mimic DCD injury and subjected to subnormothermic perfusion
with AP39 (SNTAP) or static cold storage (SCS) for 4 h. This was followed by 4 h of reperfusion
with stressed autologous blood. Frozen renal cortical sections (n = 3 for each group) were used
for the RNAseq analysis. Differentially expressed genes were identified using RStudio (DESeq2,
alpha = 0.05), and a heap map was generated. CTR, control baseline kidney with no DCD injury or
preservation treatment (n = 1).
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